Latest News
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
Business Wire - Tue Nov 12, 6:05AM CST
Business Wire
Tue Nov 12, 6:05AM CST
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results
Business Wire - Thu Nov 7, 6:05AM CST
Business Wire
Thu Nov 7, 6:05AM CST
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
Business Wire - Wed Oct 23, 5:05AM CDT
Business Wire
Wed Oct 23, 5:05AM CDT
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polฮธ ATPase Inhibitor
Business Wire - Mon Oct 14, 6:05AM CDT
Business Wire
Mon Oct 14, 6:05AM CDT
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
Business Wire - Mon Sep 30, 3:05PM CDT
Business Wire
Mon Sep 30, 3:05PM CDT
Alberta Enterprise Corporation invests US$7.5 million into Amplitude precision medicine fund
Newswire.ca - Tue Jul 16, 8:00AM CDT
Newswire.ca
Tue Jul 16, 8:00AM CDT
/CNW/ - Alberta Enterprise Corporation (AEC) announced today that it has invested US$7.5 million into Amplitude Ventures' US$192-million Fund II to give early...
Amplitude Ventures Closes $263 Million Precision Medicine Venture Fund
Newswire.ca - Tue May 28, 7:00AM CDT
Newswire.ca
Tue May 28, 7:00AM CDT
/CNW/ - Amplitude Ventures, a full-stack venture capital firm focused on investing in precision medicine at the intersection of biology and AI, today announced...
Small Cap Massively Bid Following Key Q1 Earnings Beat
AllPennyStocks.com - Wed May 8, 9:24AM CDT
AllPennyStocks.com
Wed May 8, 9:24AM CDT
A biotech company is turning heads so far during Wednesdayโs premarket hours following the company reporting higher than expected revenue and EPS. According to a handful of releases, the companyโs EPS of $0.30 beat estimates by a staggering $0.32, and the revenue of $52.4M beat by $14M.Traders were quick to...
Market movers: Stocks seeing action on Tuesday - and why
The Globe and Mail - Tue Feb 13, 8:35AM CST
The Globe and Mail
Tue Feb 13, 8:35AM CST
A survey of North American equities heading in both directions
Wall Street Thinks This Cathie Wood Stock Could Jump by 187%
Motley Fool - Wed Aug 16, 2023
Motley Fool
Wed Aug 16, 2023
This small-cap biotech stock holds enormous growth potential.
Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors
Business Wire - Fri Apr 28, 2023
Business Wire
Fri Apr 28, 2023
Repare Therapeutics Inc. (โRepareโ or the โCompanyโ) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Susan Molineaux, Ph.D., to its Board of Directors, effective as of the date of the...
Repare Therapeutics Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors at the 2023 AACR Annual Meeting
Business Wire - Tue Apr 18, 2023
Business Wire
Tue Apr 18, 2023
Repare Therapeutics Inc. (โRepareโ or the โCompanyโ) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today presented initial data from its ongoing Phase 1/2 TRESR clinical trial evaluating camonsertib (RP-3500/RG6526,...
Repare Therapeutics Announces Plenary Oral Presentation at the 2023 AACR Annual Meeting on Camonsertib and Additional Data Presentations on RP-6306
Business Wire - Tue Mar 14, 2023
Business Wire
Tue Mar 14, 2023
Repare Therapeutics Inc. (โRepareโ or the โCompanyโ) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the data from the Phase I/II trials evaluating camonsertib (RP-3500/RG6526, partnered with Roche) in...
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Business Wire - Tue Feb 28, 2023
Business Wire
Tue Feb 28, 2023
Repare Therapeutics Inc. (โRepareโ or the โCompanyโ) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2022.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repare Therapeutics Inc. - RPTX
PR Newswire - Mon Feb 13, 2023
PR Newswire
Mon Feb 13, 2023
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ: RPTX). Such...
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Repare Therapeutics Inc. (RPTX) Investigation
Business Wire - Wed Feb 8, 2023
Business Wire
Wed Feb 8, 2023
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Repare Therapeutics Inc. (โRepareโ or the โCompanyโ) (NASDAQ: RPTX). Investors who purchased Repare securities are...
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
Business Wire - Thu Feb 2, 2023
Business Wire
Thu Feb 2, 2023
Repare Therapeutics Inc. (โRepareโ or the โCompanyโ) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in February and...
Repare Therapeutics Receives $1.5 Million (ยฅ200 million) Payment from Ono Pharmaceuticals
Business Wire - Thu Jan 19, 2023
Business Wire
Thu Jan 19, 2023
Repare Therapeutics Inc. (โRepareโ or the โCompanyโ) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that the Company has received an approximately $1.5 million (ยฅ200 million) research service payment from Ono...
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
Business Wire - Mon Dec 19, 2022
Business Wire
Mon Dec 19, 2022
Repare Therapeutics Inc. (โRepareโ or the โCompanyโ) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today...
Repare Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
Business Wire - Wed Nov 9, 2022
Business Wire
Wed Nov 9, 2022
Repare Therapeutics Inc. (โRepareโ or the โCompanyโ) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2022.
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
Business Wire - Mon Nov 7, 2022
Business Wire
Mon Nov 7, 2022
Repare Therapeutics Inc. (โRepareโ or the โCompanyโ) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in November. Details...
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
Business Wire - Wed Sep 7, 2022
Business Wire
Wed Sep 7, 2022
Repare Therapeutics Inc. (โRepareโ or the โCompanyโ) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in September. Details...
Repare Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
Business Wire - Thu Aug 4, 2022
Business Wire
Thu Aug 4, 2022
Repare Therapeutics Inc. (โRepareโ or the โCompanyโ) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2022.
Repare Therapeutics to Participate at the Goldman Sachs 43rd Annual Global Healthcare Conference
Business Wire - Tue Jun 7, 2022
Business Wire
Tue Jun 7, 2022
Repare Therapeutics Inc. (โRepareโ or the โCompanyโ) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Goldman Sachs 43rd...
Why Repare Therapeutics Stock Is Skyrocketing Today
Motley Fool - Thu Jun 2, 2022
Motley Fool
Thu Jun 2, 2022
The company just announced a major collaboration with multinational pharmaceutical giant Roche.